
After rebuffing Biogen, Sage pairs off with Supernus
Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million, bringing together two companies working on central nervous system therapies that have suffered recent setbacks. The terms include an upfront payment of …